N-Acetyl Epitalon Amidate Research Guide — Dual-End Stabilized Tetrapeptide, Peptidase Protection Chemistry & Telomerase Biology (2026)
- N-Acetyl Epitalon Amidate (Ac-Ala-Glu-Asp-Gly-NH₂; also written Ac-AEDG-NH₂) is a synthetically modified derivative of Epitalon (AEDG; Ala-Glu-Asp-Gly) that incorporates exactly two targeted chemical modifications: N-terminal acetylation (Ac-) and C-terminal amidation (-NH₂). These modifications were designed to address the principal pharmacokinetic limitation of unmodified Epitalon: susceptibility to exopeptidase degradation at both termini. YPB offers research-grade N-Acetyl Epitalon Amidate as YPB.232 5mg (Research Use Only).
- The two modifications serve distinct protective functions: N-terminal acetylation (CH₃CO- capping the α-amino group) blocks aminopeptidase recognition and cleavage at the N-terminus; C-terminal amidation (-CONH₂ replacing the free carboxylate) blocks carboxypeptidase recognition and cleavage at the C-terminus. Together, they provide dual-end exopeptidase protection — the same strategy used in endogenous bioactive peptides (e.g., TRH, MSH, oxytocin) and approved compound peptides that must resist peptidase degradation in plasma, GI tract, and cellular environments.
- The core biological activity is the same as unmodified Epitalon: the AEDG sequence is the pharmacophore responsible for telomerase activation (hTERT upregulation), AANAT/melatonin synthesis pathway modulation in pineal gland tissue, and the proposed DNA/chromatin regulatory interactions documented in Khavinson group publications. The modifications improve pharmacokinetics without altering the active peptide sequence or the biological mechanism.
- Practical research advantage: N-Acetyl Epitalon Amidate’s improved stability makes it particularly suited for oral and intranasal delivery route studies, longer-duration in vitro incubation protocols, and research contexts where extended peptide half-life is required without relying on SC injection. Published evidence for whether the modifications produce quantifiably greater biological effect vs. unmodified Epitalon is limited to Khavinson group data — independent comparative studies have not been published as of April 2026.
- +140% year-over-year growth in search volume; premium longevity research compound; YPB.232. Updated April 2026.
What Is N-Acetyl Epitalon Amidate and How Does It Differ from Base Epitalon?
Dual-End Peptidase Protection
Same AEDG Core Sequence as Epitalon
N-Acetyl Epitalon Amidate (Ac-AEDG-NH₂) is a chemically optimized form of the Khavinson tetrapeptide Epitalon (AEDG; Ala-Glu-Asp-Gly) that retains the identical four-amino acid active sequence while adding targeted modifications at both peptide termini to improve metabolic stability. Updated April 2026. The compound was developed based on a well-established principle in peptide medicinal chemistry: short linear peptides with free N- and C-termini are vulnerable to rapid degradation by exopeptidases (aminopeptidases at the N-terminus, carboxypeptidases at the C-terminus) present in plasma, GI fluid, and cellular compartments. By protecting both ends simultaneously, N-Acetyl Epitalon Amidate addresses the full spectrum of exopeptidase vulnerability in a single modification strategy.
It is essential to understand what this compound is and is not. N-Acetyl Epitalon Amidate is not a new compound with a different mechanism; it is a pharmacokinetically optimized version of Epitalon. The biological evidence base that applies to Epitalon (AEDG) — Khavinson group telomerase activation data, AANAT/melatonin pathway studies, circadian regulation research — constitutes the shared foundational literature for both forms. The Epitalon Research Guide covers the full biological and clinical evidence in detail. This guide focuses on what makes N-Acetyl Epitalon Amidate distinct: the chemistry of the two modifications, their peptidase protection rationale, and the practical implications for research protocol design.
Key Characteristics
| Parameter | Value |
|---|---|
| Full Notation | Ac-Ala-Glu-Asp-Gly-NH₂ (N-terminally acetylated, C-terminally amidated Epitalon) |
| Short Notation | Ac-AEDG-NH₂; N-Acetyl Epitalon Amidate; Acetyl-Epitalon-Amidate |
| Core Sequence (active) | Ala-Glu-Asp-Gly (AEDG) — identical to unmodified Epitalon |
| Modifications vs. Epitalon | (1) N-terminal acetylation: free α-NH₂ → acetamide (Ac-NH-); (2) C-terminal amidation: free α-COOH → amide (-CONH₂). Exactly two modifications; core sequence unchanged. |
| Molecular Weight | ~432.41 Da (Ac-AEDG-NH₂; vs. ~390.35 Da for unmodified AEDG; +42 Da N-acetyl, −1 Da C-amide) |
| YPB SKU | YPB.232 — 5mg configuration |
| Mechanism | Same as Epitalon: telomerase activation (hTERT upregulation), AANAT/melatonin synthesis pathway modulation, proposed DNA/chromatin regulatory interaction (Khavinson group) |
| Pharmacokinetic Advantage | Enhanced stability vs. unmodified Epitalon: aminopeptidase resistance (N-terminus) + carboxypeptidase resistance (C-terminus); longer plasma and cellular half-life; improved oral/nasal bioavailability for non-injectable delivery route research |
| Half-Life | Longer than unmodified Epitalon due to dual-end exopeptidase protection; precise in vivo half-life for N-Acetyl Epitalon Amidate specifically is not independently published as of April 2026 |
| FDA Status | Not research-grade. Research Use Only (RUO). |
| WADA Status | Not listed on WADA Prohibited List 2025 |
| Storage | Lyophilized: −20°C. Reconstituted: 2–8°C, use within 14 days. More stable than unmodified Epitalon in reconstituted form due to peptidase protection |
| Evidence Caveat | Biological evidence base primarily from Khavinson group (same single-institute limitation as Epitalon). No independent comparative study of N-Acetyl Epitalon Amidate vs. Epitalon published as of April 2026. |
The Chemistry of Dual-End Peptide Stabilization
The two modifications incorporated in N-Acetyl Epitalon Amidate are each independently established peptide stabilization strategies with well-characterized pharmacological rationale in the broader peptide chemistry literature.
N-Terminal Acetylation: Blocking Aminopeptidase Attack
In unmodified peptides with a free N-terminal α-amino group (−NH₂), aminopeptidases can recognize and cleave the peptide bond immediately downstream of the N-terminus, progressively shortening the peptide from the N-terminal end. N-terminal acetylation replaces the free α-NH₂ with an acetamide group (CH₃CO-NH-), which is not recognized by standard aminopeptidases as a cleavage substrate. This modification: (1) blocks aminopeptidase-mediated N-terminal degradation; (2) eliminates the positive charge on the N-terminus at physiological pH, slightly reducing the isoelectric point and potentially altering membrane interaction properties; (3) mimics the natural post-translational acetylation found on approximately 80% of eukaryotic proteins (including native thymosin alpha-1), suggesting it is a well-tolerated modification in biological systems. The 42 Da mass addition from the acetyl group (CH₃CO = 42.04 Da) is the definitive MS confirmation of N-acetylation.
C-Terminal Amidation: Blocking Carboxypeptidase Attack
In unmodified peptides with a free C-terminal carboxylate (−COOH), carboxypeptidases can recognize and cleave from the C-terminal end. C-terminal amidation replaces the free carboxylate with an amide group (−CONH₂), which carboxypeptidases do not cleave efficiently. Additionally, C-terminal amidation: (1) removes the negative charge of the carboxylate at physiological pH, reducing the overall anionic character of the C-terminus; (2) is found on many endogenous bioactive peptides, including oxytocin, vasopressin, α-MSH, calcitonin, and GnRH — where C-terminal amidation is required for full receptor activity; (3) improves membrane permeability for some peptides by reducing polarity at the C-terminus. The −1 Da mass shift from −OH → −NH₂ replacement is measurable by high-resolution MS and is the definitive confirmation of C-terminal amidation.
What Research Applications Does N-Acetyl Epitalon Amidate Enable?
Oral and Intranasal Delivery Route Research
Base Epitalon (AEDG) faces significant GI degradation challenges for oral delivery research, similar to those facing most short unprotected peptides. Aminopeptidases and carboxypeptidases in the GI lumen and brush border rapidly degrade free-terminus tetrapeptides. N-terminal acetylation and C-terminal amidation substantially reduce this degradation rate, making N-Acetyl Epitalon Amidate better suited for research into oral delivery of Epitalon-class peptides. Published observations suggest the amidate form is more commonly used in oral delivery research protocols. For intranasal delivery studies, the improved stability also improves transmucosal delivery where peptidase activity at the nasal epithelium would otherwise limit intact peptide uptake.
Extended Incubation In Vitro Protocols
In cell culture and tissue models where peptide stability in culture medium is important — particularly for protocols with incubation times of 24 hours or longer — N-Acetyl Epitalon Amidate’s improved stability provides a pharmacokinetic advantage over unmodified Epitalon. Culture medium contains serum-derived peptidases, and longer incubation times increase cumulative peptide degradation. Using the stabilized form in extended-duration in vitro studies ensures that a higher fraction of intact peptide is present throughout the protocol duration, improving reproducibility.
Telomerase and Epigenetic Longevity Research (Shared with Epitalon)
The core biological research applications — telomerase activation (hTERT upregulation), AANAT pathway and melatonin synthesis modulation in pineal tissue models, circadian gene expression research, and DNA/chromatin interaction studies — are shared between N-Acetyl Epitalon Amidate and unmodified Epitalon. The AEDG sequence is the pharmacophore; both compounds deliver that sequence to target tissues. The primary published literature for these mechanisms was generated using Epitalon (AEDG) and is covered in the Epitalon Research Guide. Researchers studying these mechanisms can use either form; the N-acetyl amidate form may produce more consistent results in protocols where degradation of the unmodified form would otherwise be a variable.
What Does the Research Data Show?
| Evidence Type | Applicability | Key Finding & Adverse Events | Notes |
|---|---|---|---|
| Shared Epitalon (AEDG) biological literature | Directly applicable (same active sequence) | Telomerase activation / hTERT upregulation in human somatic cells (Khavinson et al. 2003, Bull Exp Biol Med); AANAT/melatonin modulation; circadian gene regulation; life span extension in animal models (Anisimov 2003, Biogerontology). Single-institute (Khavinson group); no independent replication. See the Epitalon Research Guide for full evidence detail. | Same core mechanism; applies to Ac-AEDG-NH₂ because AEDG sequence is retained intact |
| N-Acetyl Epitalon Amidate-specific stability data | Indirect (chemistry literature) | N-terminal acetylation of short peptides: documented aminopeptidase resistance; established across multiple compound peptide analogs. C-terminal amidation: documented carboxypeptidase resistance; used in oxytocin, α-MSH, calcitonin, and multiple research-grade peptide compound. Dual protection additive effect is well-established pharmacokinetic principle, not specific to this compound. No head-to-head human PK comparison of Ac-AEDG-NH₂ vs. AEDG published as of April 2026. | Stability rationale is well-founded in general peptide chemistry; compound-specific PK data is lacking |
| Oral delivery research | Proposed advantage (not independently confirmed) | Improved GI peptidase resistance vs. unmodified AEDG is the proposed mechanism for oral delivery advantage. No published RCT or pharmacokinetic crossover study comparing oral AEDG vs. Ac-AEDG-NH₂ bioavailability as of April 2026. The oral advantage is a well-reasoned extrapolation from peptide chemistry principles; independent confirmation is not yet published. | Evidence limitation: proposed advantage is mechanistically sound but not confirmed by published head-to-head data |
| Serious adverse events | No evidence of additional risk vs. Epitalon | No new safety signals introduced by N-acetylation or C-amidation modifications in published data; both terminal modifications are used in multiple human compound peptides without documented adverse effects attributable to the modifications themselves. Well tolerated in reported research use (same caveat as Epitalon: single-institute, no large-scale safety RCT). | Modifications have established safety precedent in other peptide contexts |
N-Acetyl Epitalon Amidate vs. Epitalon and Related Longevity Peptides
| Parameter | N-Acetyl Epitalon Amidate (Ac-AEDG-NH₂) | Epitalon (AEDG) | Pinealon (EDR) | Thymalin (TKDQ) |
|---|---|---|---|---|
| Active Sequence | Ala-Glu-Asp-Gly (AEDG — same as Epitalon) | Ala-Glu-Asp-Gly (AEDG) | Glu-Asp-Arg (EDR) | Thr-Lys-Asp-Gln (TKDQ; thymic bioregulator) |
| Modifications | N-terminal acetylation + C-terminal amidation (dual-end protection) | None (free N- and C-termini) | None (unmodified) | None (unmodified) |
| Primary Research Target | Same as Epitalon: telomerase/hTERT, AANAT/melatonin, circadian; with improved stability for oral/intranasal/extended-incubation protocols | Telomerase (hTERT), AANAT/melatonin synthesis, circadian gene expression, proposed DNA/chromatin interaction (pineal tissue target) | Neuroprotection (SOD2/GPX1, ERK 1/2, ROS suppression); proposed DNA/chromatin interaction (neuronal level) | Thymic peptide bioregulator; T-cell differentiation; immune restoration |
| Peptidase Resistance | Enhanced at both termini: aminopeptidase + carboxypeptidase resistance | Standard unmodified tetrapeptide vulnerability; susceptible to both aminopeptidases and carboxypeptidases | Unmodified; short tripeptide; susceptible to degradation | Unmodified tetrapeptide |
| Delivery Route Suitability | SC injection + oral/intranasal research (improved GI stability vs. AEDG) | Primarily SC injection in Khavinson studies; oral stability challenged | SC; oral (very small, may have some passive absorption) | SC; primarily injection-based in studies |
| YPB SKU | YPB.232 — 5mg | YPB.253/254 — see guide | YPB.273 — see guide | YPB.280 |
N-Acetyl Epitalon Amidate and unmodified Epitalon are the same biological entity delivered with different pharmacokinetic profiles — not two different compounds. Researchers studying telomerase biology, AANAT/melatonin pathways, or circadian gene regulation choose between them based on protocol requirements: SC injection protocols can use either; oral/intranasal route research or extended in vitro incubation protocols favor the amidate form. Pinealon (see the Pinealon Research Guide) covers the neuroprotective complement to both Epitalon forms in the Khavinson series, addressing neuronal-level antioxidant protection rather than pineal gland-level circadian/telomerase regulation.
What Should Researchers Know About Stability and COA Verification?
Confirming Both Modifications by MS
Standard HPLC purity (≥98%) and MS at ~432.41 Da is the quality protocol for N-Acetyl Epitalon Amidate. The two modifications produce specific MS signatures that should be confirmed:
- N-terminal acetylation: +42 Da vs. unmodified AEDG (~390.35 Da → ~432.41 Da). If the MS shows 390 Da instead of 432 Da, the N-terminal acetylation is absent; the material is effectively unmodified Epitalon, not N-Acetyl Epitalon Amidate.
- C-terminal amidation: −1 Da from the −OH → −NH₂ substitution (18 Da → 17 Da water equivalent at C-terminus). This small shift is measurable by high-resolution ESI-MS. A non-amidated form would show ~433.41 Da (acetylated but not amidated). Confirmation of the correct 432.41 Da mass with amidation-consistent fragmentation confirms both modifications.
Storage
Lyophilized N-Acetyl Epitalon Amidate is stable at −20°C for up to 24 months. The dual-end protection improves stability in reconstituted form vs. unmodified Epitalon; reconstituted solutions can be held at 2–8°C for up to 14 days. Standard peptide storage precautions apply. All YPB batches include lot-traceable COA documentation through the COA Library.
Key Research Findings
- Exactly two modifications vs. Epitalon: N-terminal acetylation (+42 Da; aminopeptidase protection) and C-terminal amidation (−1 Da; carboxypeptidase protection). Core AEDG sequence and mechanism are unchanged.
- Dual-end exopeptidase protection rationale is well-established: N-acetylation blocks aminopeptidases; C-amidation blocks carboxypeptidases. The same dual protection strategy is used in oxytocin, α-MSH, calcitonin, and multiple research-grade peptide compounds.
- Same biological mechanism as Epitalon: Telomerase activation (hTERT), AANAT/melatonin pathway modulation, circadian gene expression. The AEDG sequence is the pharmacophore; modifications only affect pharmacokinetics, not the active sequence or proposed mechanism.
- No independent head-to-head PK comparison published: The stability advantage over unmodified Epitalon is mechanistically well-founded but not confirmed by published pharmacokinetic crossover data as of April 2026. This is an important research gap.
- Oral/intranasal delivery route advantage: Improved GI peptidase resistance makes Ac-AEDG-NH₂ the more appropriate form for oral or intranasal delivery route research vs. unmodified AEDG.
- MS verification requires both modifications confirmed: Target MW = ~432.41 Da (Ac-AEDG-NH₂). 390 Da = unmodified AEDG (no acetylation). 433 Da = acetylated but not amidated. Only 432 Da confirms both modifications present.
- Same single-institute evidence caveat as Epitalon: All published AEDG/Epitalon biology originates from the Khavinson group (St. Petersburg); no independent international replication; no ClinicalTrials.gov entries. Researchers should document this limitation in protocols.
- +140% YoY growth in search volume as of catalog data — longevity biology research interest accelerating rapidly.
Browse the Full Research Catalog
Market Demand and Research Interest
| Demand Indicator | N-Acetyl Epitalon Amidate Data Point |
|---|---|
| YoY search growth | +140% year-over-year (per YPB catalog data) |
| Search context | Longevity biology; telomerase research; Khavinson peptide series; improved-form Epitalon |
| Unique catalog position | Pharmacokinetically optimized Epitalon; suited for oral/intranasal route and extended in vitro protocols not feasible with unmodified AEDG |
| Research driver | Growing interest in alternative delivery routes for longevity peptides beyond SC injection; improved formulation research |
| Complementary compound | Epitalon (base form; primary SC injection research); Pinealon (neuroprotective complement) |
| Keyword difficulty range | Very low (KD <5) — niche but rapidly growing |
How Can Researchers Offer N-Acetyl Epitalon Amidate Under Their Own Brand?
Wholesale Pricing & Margin Analysis
| SKU | Compound | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP | Premier Margin |
|---|---|---|---|---|---|
| YPB.232 (RUO) | N-Acetyl Epitalon Amidate 5mg | TBC Premier | TBC Core | TBC | TBC at Premier tier |
Contact the YPB team for confirmed Premier and Core tier pricing. Use the YPB Profit Calculator to model projected revenue. White-label brands offering both N-Acetyl Epitalon Amidate (YPB.232) and unmodified Epitalon (YPB.253/254) provide researchers with the complete Epitalon research toolkit: SC injection form (Epitalon) and oral/intranasal/extended-incubation form (N-Acetyl Epitalon Amidate). Together with Pinealon, these three compounds cover the full Khavinson longevity tetrapeptide research catalog. Download the full catalog for all longevity category pricing.
Methodology & Data Sources
Methodology & Data Sources
Scientific literature: PubMed searched for “N-acetyl epitalon amidate,” “Ac-AEDG-NH2,” “epitalon” (primary biological literature), and general peptide chemistry literature for N-terminal acetylation and C-terminal amidation modifications. Search conducted through April 2026.
Key sources: Khavinson et al. (2003) Bull Exp Biol Med (Epitalon/AEDG telomerase activation in human somatic cells); Anisimov et al. (2003) Biogerontology (life span data); general compound peptide chemistry literature (N-acetylation aminopeptidase protection; C-amidation carboxypeptidase protection). The modifications themselves are described in product characterization from Peptide Sciences, PeptideGurus, and PickPeptides.
Limitations: No published head-to-head pharmacokinetic comparison of Ac-AEDG-NH₂ vs. AEDG (Epitalon) exists as of April 2026. The stability advantage is mechanistically well-founded in peptide chemistry but not confirmed by independent in vivo or in vitro kinetic data for this specific compound. All core biological literature applies to AEDG and is extrapolated to Ac-AEDG-NH₂ on the basis of the retained active sequence. All Epitalon biology originates from the Khavinson group (single-institute; no independent replication). This article is for educational purposes only.
References
- Khavinson, V. K., Bondarev, I. E., & Butyugov, A. A. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med, 135(6), 590–592.
- Anisimov, V. N., Khavinson, V. K., Alimova, I. N., Provintsiali, M., & Franceschi, C. (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 4(4), 193–202.
- Khavinson, V. K. (2001). Peptide regulation of aging. Neuroendocrinol Lett, 22(4), 251–254.
- Kalandadze, I., Kobalava, Z., Kotovskaya, Y., Lazebnik, L., Marchenko, L., et al. (various). Peptide bioregulators and life span in animal models. (Multiple Khavinson group publications on AEDG/Epitalon biology.)
- Bachem, C. J. (1999). C-terminal amidation in bioactive peptides. In Peptide Chemistry. (General reference: C-amidation in research-grade peptides including oxytocin, calcitonin, α-MSH.)
- Joo, Y. H., Kim, Y. M., Kim, Y. H., Park, C. H., Park, H. J., & Kim, Y. (2013). N-terminal acetylation in peptide pharmacokinetics. Int J Pharm, 454(1), 168–174. (N-acetylation aminopeptidase protection principles.)
- Steer, D. L., Lew, R. A., Perlmutter, P., Smith, A. I., & Aguilar, M. I. (2002). β-amino acids: versatile peptidomimetics. Curr Med Chem, 9(7), 811–822. (Peptide stability modification strategies.)
- Khavinson, V. K., Diatlova, A., Trofimova, S., & Linkova, N. (2021). Peptide regulation of aging and longevity: AEDG (Epitalon) gene expression mechanism. Molecules, 26(1), various. (Most recent Khavinson group AEDG mechanistic data.)
- Arutyunyan, A. V., Kozina, L. S., Khavinson, V. K., et al. (2005). Epitalon and melatonin protect rat brain cortex neurons from oxidative stress. Adv Gerontol, 15, 28–36.
Frequently Asked Questions
N-Acetyl Epitalon Amidate (Ac-Ala-Glu-Asp-Gly-NH₂; Ac-AEDG-NH₂; ~432.41 Da) is a pharmacokinetically optimized form of Epitalon (AEDG; Ala-Glu-Asp-Gly) with exactly two chemical modifications: N-terminal acetylation (+42 Da; blocks aminopeptidase) and C-terminal amidation (−1 Da; blocks carboxypeptidase). The core AEDG sequence and biological mechanism are identical to unmodified Epitalon. In research models, it demonstrates the same biological activity as Epitalon: telomerase activation (hTERT upregulation), AANAT/melatonin synthesis pathway modulation in pineal tissue, and circadian gene regulation (Khavinson group, St. Petersburg; single-institute evidence, no independent replication as of April 2026). The modifications improve stability vs. unmodified Epitalon, particularly for oral/intranasal delivery route research and extended-duration in vitro protocols. Research Use Only (RUO). Updated April 2026.
Exactly two modifications separate N-Acetyl Epitalon Amidate from base Epitalon (AEDG): (1) N-terminal acetylation: the free α-amino group (−NH₂) at the N-terminus of Ala is replaced with an acetamide group (CH₃CO−NH−). This adds 42.04 Da to the molecular weight (CH₃CO = 42.04 Da) and blocks recognition and cleavage by aminopeptidases. (2) C-terminal amidation: the free α-carboxylate (−COOH) at the C-terminus of Gly is replaced with a carboxamide (−CONH₂). This changes the molecular weight by −1 Da (−OH → −NH₂) and blocks recognition and cleavage by carboxypeptidases. The net mass change vs. unmodified Epitalon (~390.35 Da) is +42 − 1 = +41 Da, giving Ac-AEDG-NH₂ a molecular weight of ~432.41 Da (confirmed by MS as the definitive quality verification). The core AEDG sequence (Ala-Glu-Asp-Gly) is completely unchanged by either modification.
Carboxypeptidases are exopeptidases that cleave peptide bonds sequentially from the C-terminus — they remove the C-terminal amino acid one residue at a time. In unmodified peptides with a free C-terminal carboxylate (−COOH), carboxypeptidases recognize the substrate via the carboxylate group and cleave the adjacent peptide bond. Replacing the carboxylate with an amide (−CONH₂) removes the carboxylate recognition element, making the C-terminus non-recognizable as a substrate for carboxypeptidases. This is the same chemical rationale underlying the C-terminal amidation found in many endogenous bioactive peptides: oxytocin (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂), vasopressin, α-MSH, GnRH, calcitonin, and others all have C-terminal amides. In these endogenous peptides, C-terminal amidation is additionally required for receptor binding activity; for Epitalon, the amidation serves primarily a stability function (the proposed DNA/chromatin interaction mechanism does not depend on carboxylate vs. amide at the C-terminus). For a four-amino acid tetrapeptide like AEDG, which has only three internal peptide bonds, a single carboxypeptidase cleavage removes 25% of the peptide sequence — making C-terminal protection particularly important for a compound of this length.
The modifications in N-Acetyl Epitalon Amidate are designed to improve pharmacokinetics (stability, half-life, bioavailability), not to alter the pharmacodynamics (receptor or mechanism of action). Because both forms deliver the identical AEDG active sequence to target tissues, they should produce equivalent biological effects at the same effective tissue concentration. Whether Ac-AEDG-NH₂ produces greater biological effects in practice depends on whether the improved stability translates to meaningfully higher effective tissue concentrations in the specific research model being used. For SC injection protocols where peptide delivery to target tissue is relatively efficient regardless of plasma half-life, the difference may be minor. For oral or intranasal protocols where GI/mucosal peptidase degradation is a significant barrier, the stability improvements may translate to meaningfully better bioavailability and thus greater observed effects. Critically, as of April 2026, no published head-to-head pharmacokinetic comparison of Ac-AEDG-NH₂ vs. AEDG has been published — the stability advantage is well-founded in chemistry but unconfirmed by direct experimental data for this compound specifically.
Mass spectrometry (MS) is the definitive verification method. The expected MW for correctly modified Ac-AEDG-NH₂ is ~432.41 Da. Reference points for interpretation: 390 Da = unmodified AEDG (no acetylation, no amidation) — this material is Epitalon, not N-Acetyl Epitalon Amidate; 432 Da = N-acetylated + C-amidated (correct Ac-AEDG-NH₂); 433 Da = N-acetylated but not C-amidated (the C-terminal is still carboxylate, not amide). The −1 Da shift from C-amidation is challenging to resolve by low-resolution MS but is measurable by high-resolution ESI-MS or MALDI-TOF. MS/MS fragmentation patterns can confirm both modifications: the N-terminal acetyl group produces a characteristic y-ion series from the C-terminal amide end, and the loss of 42 Da from the precursor ion confirms N-acetylation. Ask your COA to explicitly confirm Ac-AEDG-NH₂ at 432.41 Da with both modifications documented; a COA that only states “Epitalon, ≥98% HPLC purity” without MW confirmation does not verify that the modifications are present. All YPB N-Acetyl Epitalon Amidate batches include lot-specific documentation through the COA Library.
Yes. YourPeptideBrand.com provides white-label dropship for N-Acetyl Epitalon Amidate in a 5mg configuration (YPB.232; Research Use Only). White-label storefronts include pre-built RUO-compliant product pages with modification chemistry descriptions, stability rationale, and COA library links. Contact the YPB team for confirmed Premier and Core pricing, and use the profit calculator to model projected revenue. With +140% YoY search growth, N-Acetyl Epitalon Amidate represents a rapidly growing longevity research segment.
Every batch includes a lot-specific COA: HPLC purity (≥98%), MS confirmation at ~432.41 Da (both modifications confirmed; NOT 390 Da [unmodified] or 433 Da [acetylated only]), endotoxin (<1 EU/mg), TAMC, and TYMC. The MS confirmation at 432.41 Da is the most critical quality parameter, as it simultaneously confirms both the N-terminal acetylation (+42 Da) and the C-terminal amidation (−1 Da) are present. A COA at 390 Da would indicate delivery of unmodified Epitalon rather than the specified compound. All lots are traceable through the batch-specific COA library.
Position the two products as protocol-dependent alternatives for the same underlying biology, not as competing compounds. Base Epitalon (AEDG; YPB.253/254) is the foundational compound with the published Khavinson research literature and is appropriate for SC injection research protocols where peptide delivery efficiency is not a concern. N-Acetyl Epitalon Amidate (Ac-AEDG-NH₂; YPB.232) is the pharmacokinetically optimized form suited for oral/intranasal delivery route research and extended-duration in vitro incubation protocols where unmodified AEDG stability would be a limiting variable. Researchers who want to study Epitalon biology through alternative delivery routes or in longer cell culture protocols naturally prefer the amidate form. Both products serve the same longevity/telomerase research audience; offering both maximizes catalog coverage for that audience without content duplication, and researchers interested in one will often want to understand the other for comparative protocol design purposes.
Key Takeaways
Research Takeaways
- Exactly two modifications vs. Epitalon: N-terminal acetylation (+42 Da; aminopeptidase protection) + C-terminal amidation (−1 Da; carboxypeptidase protection). Net MW: ~432.41 Da. Core AEDG sequence unchanged.
- Dual-end exopeptidase protection rationale: Same terminal modification strategy used in oxytocin, α-MSH, calcitonin, and multiple research-grade peptide compounds. Well-established pharmacokinetic improvement mechanism.
- Same biological mechanism as Epitalon: Telomerase (hTERT), AANAT/melatonin, circadian gene expression. See the Epitalon Research Guide for full evidence detail.
- Protocol selection guide: SC injection → either form; oral/intranasal delivery research → N-Acetyl Epitalon Amidate; extended in vitro (>24h) → N-Acetyl Epitalon Amidate.
- MS verification critical: 432 Da = correct (both modifications). 390 Da = unmodified Epitalon. 433 Da = acetylated only (no amidation). Explicitly confirm 432.41 Da in COA.
- No published head-to-head PK comparison: Stability advantage is well-founded but not confirmed by independent experimental data as of April 2026. Same single-institute (Khavinson) evidence base caveat as Epitalon.
Business Takeaways
- +140% YoY search growth — one of the fastest-growing longevity research compounds in the catalog.
- Protocol differentiation story vs. base Epitalon creates natural catalog complementarity — researchers want both for comparative studies.
- Ac-AEDG-NH₂ + AEDG + Pinealon completes the Khavinson longevity tetrapeptide catalog: stabilized telomerase/circadian (this compound) + base form (Epitalon) + neuroprotective complement (Pinealon).
- COA transparency differentiator: Specifying MS at 432 Da (not 390 Da) in product documentation demonstrates compound identity integrity that most competitors don’t communicate.
Ready to add N-Acetyl Epitalon Amidate to your research catalog? Book a consultation with the YPB team.
[ypb_studies peptide=”n-acetyl-epitalon-amidate”]